Literature DB >> 9148719

Experience of clinical use of the Odstock dropped foot stimulator.

J Burridge1, P Taylor, S Hagan, I Swain.   

Abstract

The Odstock dropped foot stimulator (ODFS) is a simple functional electrical stimulation (FES) device for the correction of dropped foot. Improved reliability, fine control of stimulation parameters, and careful application and follow-up have let to 86% compliance. Data on 56 patients (50 patients with hemiplegia, 5 patients with multiple sclerosis, and 1 patient with spinal cord injury) who have used the system for between 6 and 18 months are presented and show a statistically significant increase in walking speed with the stimulator at 3 months of 14% (p < 0.001); decreased effort of walking, measured as physiological cost index (PCI), of 37% (p < 0.001); and statistically significant improvement in functional mobility tests and questionnaires. No statistically significant carryover was seen although 3 patients had sufficient improvement in active ankle control and gait parameters to no longer need the stimulator. Six patients who used the stimulator all day every day had a problem with skin irritation, which we have not yet been able to solve. Two patients discontinued use after experiencing increased spasticity in the calf.

Entities:  

Mesh:

Year:  1997        PMID: 9148719     DOI: 10.1111/j.1525-1594.1997.tb04662.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  15 in total

1.  Modified implanted drop foot stimulator system with graphical user interface for customised stimulation pulse-width profiles.

Authors:  T O'Halloran; M Haugland; G M Lyons; T Sinkjaer
Journal:  Med Biol Eng Comput       Date:  2003-11       Impact factor: 2.602

Review 2.  Integrating rehabilitation engineering technology with biologics.

Authors:  Jennifer L Collinger; Brad E Dicianno; Douglas J Weber; Xinyan Tracy Cui; Wei Wang; David M Brienza; Michael L Boninger
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

3.  Motor cortex excitability following repetitive electrical stimulation of the common peroneal nerve depends on the voluntary drive.

Authors:  Svetlana Khaslavskaia; Thomas Sinkjaer
Journal:  Exp Brain Res       Date:  2005-02-09       Impact factor: 1.972

4.  Autogenic EMG-controlled functional electrical stimulation for ankle dorsiflexion control.

Authors:  Hojun Yeom; Young-Hui Chang
Journal:  J Neurosci Methods       Date:  2010-08-14       Impact factor: 2.390

Review 5.  Technological advances in interventions to enhance poststroke gait.

Authors:  Lynne R Sheffler; John Chae
Journal:  Phys Med Rehabil Clin N Am       Date:  2013-05       Impact factor: 1.784

6.  Randomized controlled trial of surface peroneal nerve stimulation for motor relearning in lower limb hemiparesis.

Authors:  Lynne R Sheffler; Paul N Taylor; Douglas D Gunzler; Jaap H Buurke; Maarten J Ijzerman; John Chae
Journal:  Arch Phys Med Rehabil       Date:  2013-02-08       Impact factor: 3.966

7.  Spatiotemporal, kinematic, and kinetic effects of a peroneal nerve stimulator versus an ankle foot orthosis in hemiparetic gait.

Authors:  Lynne R Sheffler; Stephanie Nogan Bailey; Richard D Wilson; John Chae
Journal:  Neurorehabil Neural Repair       Date:  2012-11-27       Impact factor: 3.919

8.  Motor neuroprosthesis for promoting recovery of function after stroke.

Authors:  Luciana A Mendes; Illia Ndf Lima; Tulio Souza; George C do Nascimento; Vanessa R Resqueti; Guilherme Af Fregonezi
Journal:  Cochrane Database Syst Rev       Date:  2020-01-14

9.  Electromyography and sonomyography analysis of the tibialis anterior: a cross sectional study.

Authors:  Antonio I Cuesta-Vargas; Maria Ruiz-Muñoz
Journal:  J Foot Ankle Res       Date:  2014-02-08       Impact factor: 2.303

10.  Continuous gait cycle index estimation for electrical stimulation assisted foot drop correction.

Authors:  Christine Azevedo Coste; Jovana Jovic; Roger Pissard-Gibollet; Jérôme Froger
Journal:  J Neuroeng Rehabil       Date:  2014-08-09       Impact factor: 4.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.